

SPO MEDICAL UNVEILS NEW OXIMETRY DEVICES FOR EUROPEAN MARKETS

PulseOx 6000™ and PulseOx 6100™ to be launched at MEDICA in Germany

New York, N.Y. – November 14, 2007. SPO Medical Inc. (OTCBB: [SPOM](#)), a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices, today announced that the *PulseOx 6000™* and *PulseOx 6100™*, two new oximetry devices, will be formally introduced to the public at the 39th MEDICA World Forum for Medicine in Düsseldorf, Germany between 14th – 17th November, 2007.

The PulseOx 6000™ (finger device) and PulseOx 6100™ (hand-held device) are both designed for medical professionals, hospitals and managed care facilities. Based on SPO Medical's proprietary patented algorithms, both the PulseOx 6000™ and PulseOx 6100™ use Reflective Pulse Oximetry (RPO) technology for accurate and reliable measurements of blood oxygen saturation and heart rate, utilizing new AutoSpot™ technology to read in low perfusion measurements. The products have been granted CE Mark of approval by the European Union and will be commercially available early in the first quarter of 2008.

These ground-breaking medical devices follow the watershed success of the PulseOx 5500™. Earlier this year, the Company announced that it sold over 100,000 of the pulse oximetry units, marking a sales milestone that has been achieved within three years of the company's first introduction of the commercial product.

"We are thrilled to introduce the medical community to PulseOx 6000™ and PulseOx 6100™ at MEDICA, the leading medical exhibition in the world," said Michael Braunold, President and Chief Executive Officer of SPO Medical. "I am confident that SPO Medical will continue to unveil new life-saving and life-enhancing products and move forward in implementing a thoughtful strategy to expand our businesses."

MEDICA, the international hub for the medical trade, introduces the medical industry to the latest products for in-patient and out-patient care: electromedical and laboratory equipment, medical technology, diagnostics, pharmaceuticals and medical supplies as well as physiotherapy and orthopedic technology, communication and information technology, facility management, clothing, medical furniture and equipment and building technology. For more information on MEDICA, go to www.medica.de.

SPO Medical will be located in Hall 13/D 20 and their executives will be available to answer questions along with demonstrating the new product offerings.

About SPO Medical:

SPO Medical ([SPOM](#)) a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices to capture life-saving and life-enhancing information within four key markets: medical care; home and remote-care; sports and wellness; and safety and security. Its patented technology uses information gathered from the reflectance of light on the human blood stream, in a non-invasive manner, to monitor key vital signs. The Company distributes its products through a network of distributors and also licenses its technologies to appropriate client corporations for commercialization and distribution. For more information, visit www.spomedical.com.

Safe Harbor:

This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry, and that reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to, changes in economic conditions generally and the medical devices market specifically, changes in technology, legislative or regulatory changes that affect us, the availability of working capital, changes in costs and the availability of goods and services, the introduction of competing products, planned product launches, changes in our operating strategy or development plans, our ability to attract and retain qualified personnel, and the risks and uncertainties discussed under the heading "Risk Factors" in Item 1 of our Annual Report on Form 10-KSB for the fiscal year ended December 31, 2006. We undertake no obligation to revise or update any forward-looking statement for any reason.

#

SPO Medical Contact:

Michael Braunold, CEO
braunold@spomedical.com
011-972-9-7643570

Seventh Circle Consulting Contact:

Christine J. Petraglia
investors@spomedical.com
1-646-354-8886